SRPT250117C88000
- 0.00
- 0.000.00%
Sarepta Therapeutics Newsroom
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $195 to $217
Sarepta Therapeutics' Strong Market Position and Elevidys' Promising Prospects Drive Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT) and Roche Holding AG (OtherRHHVF)
Sarepta Therapeutics Price Target Maintained With a $202.00/Share by Needham
Sarepta Therapeutics Analyst Ratings
Buy Rating Reaffirmed for Sarepta Therapeutics Following Positive EMBARK Study Results
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $165
RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
TD Cowen Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $75 to $203
Sarepta Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Temporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta Therapeutics
Sarepta Therapeutics Analyst Ratings
Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217
Sarepta Therapeutics (SRPT) Gets a Buy From Piper Sandler
Sarepta Therapeutics: Strong Elevidys Launch and Promising Pipeline Drive Buy Rating
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $195
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200